Recent progress and clinical importance on pharmacogenetics in cancer therapy.
Recent progress and clinical importance on pharmacogenetics in cancer therapy.
复制标题
在癌症治疗中对药物遗传学的最新进展和临床重要性。
DOI：
10.1515/cclm.2011.715
复制
发表时间：
2011-10
影响因子：
6.8
通讯作者：
Innocenti F
中科院分区：
文献类型：
--
作者：
Soh TI;Yong WP;Innocenti F
最近的进展为确定癌症治疗效果的预后和预测标记提供了前所未有的机会。遗传标记可用于排除不能从治疗中获益的患者，排除有严重毒性高风险的患者，并调整剂量。标记物发现的基因组方法现在包括全基因组关联研究和肿瘤DNA测序。现在的挑战是选择有足够证据将其转化为临床的标记物。障碍包括许多这些标记物固有的低频率，通过试验的漫长验证过程，以及立法和经济障碍。为了更快地回答有关某些标记物的问题，浓缩设计的试验越来越受欢迎，特别是考虑到最近几个月出现的引人注目的第一阶段结果。肿瘤学的个性化医疗离现实又近了一步。
Recent advances have provided unprecedented opportunities to identify prognostic and predictive markers of efficacy of cancer therapy. Genetic markers can be used to exclude patients who will not benefit from therapy, exclude patients at high risk of severe toxicity, and adjust dosing. Genomic approaches for marker discovery now include genome-wide association studies and tumor DNA sequencing. The challenge is now to select markers for which there is enough evidence to transition them to the clinic. The hurdles include the inherent low frequency of many of these markers, the lengthy validation process through trials, as well as legislative and economic hurdles. Attempts to answer questions about certain markers more quickly have led to an increased popularity of trials with enrichment design, especially in the light of the dramatic phase I results seen in recent months. Personalized medicine in oncology is a step closer to reality.